EP2945628
Andrógenviðtakastillir ásamt abíraterón asetati og prednisóni til að meðhöndla krabbamein í blöðruhálskirtli
:
EP Einkaleyfi ógilt eftir andmæli:
9.1.2014:
15.4.2020:
14701865.9
:
29.4.2020:
15.5.2020
:
8.1.2034:
8.1.2022
:
ANDROGEN RECEPTOR MODULATOR IN COMBINATION WITH ABIRATERONE ACETATE AND PREDNISONE FOR TREATING PROSTATE CANCER
9.1.2014
15.4.2020
29.4.2020
15.5.2020
8.1.2022
:
Aragon Pharmaceuticals, Inc.:
10990 Wilshire Blvd. Suite 300, Los Angeles, CA 90024, US
:
CHEN, Isan:
San Diego, California 92122, US
:
HAGER, Jeffrey H.:
San Diego, California 92130, US
:
MANEVAL, Edna Chow:
San Diego, California 92130, US
:
HERBERT, Mark R.:
San Diego, California 92111, US
:
SMITH, Nicholas D.:
San Diego, California 92109, US
:
Patice ehf.:
Pósthólf 8236, 128, Reykjavík,
:
201361752842 P:
15.1.2013:
US
:
US2014010777:
9.1.2014
:
A61K 31/4439, A61K 45/06, A61P 35/00, A61P 35/04, A61P 5/28, A61P 17/14, A61K 47/10, A61K 47/34, A61K 47/44, A61K 9/48, A61K 38/09, A61K 9/00
: 8
: 15.12.2020
: 8.1.2022
: Árnason Faktor ehf.